| Name | Valacyclovir hydrochloride |
| Description | Valacyclovir hydrochloride (Valaciclovir hydrochloride) is an acyclovir prodrug that, upon metabolism, inhibits viral DNA replication. |
| In vitro | In male CD rats, Valaciclovir was absorbed orally, efficiently metabolized and rapidly distributed. |
| In vivo | Valaciclovir is the L-valine ester of aciclovir, the absorption of which occurs in the intestinal lumen and is converted to the L-valine ester of aciclovir.Valaciclovir inhibits the uptake of dipeptide transporter protein substrates, e.g., cephalosporin. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.54 mM), Sonication is recommended. DMSO : 20.4 mg/mL (56.54 mM), Sonication is recommended.
|
| Keywords | Valacyclovir hydrochloride | Valacyclovir | Valaciclovir Hydrochloride | Valaciclovir | RNASynthesis | RNA Synthesis | Inhibitor | inhibit | HSV | Herpes simplex virus | DNASynthesis | DNA Synthesis | DNA polymerase | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Thymidine | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |